Inc. (NASDAQ:INCR) Files An 8-K Financial Statements and Exhibits

Inc. (NASDAQ:INCR) Files An 8-K Financial Statements and Exhibits
Item 9.01  Financial Statements and Exhibits.

Story continues below

(d) Exhibits

99.1   Press Release dated March 31, 2021


Net Element, Inc. Exhibit
EX-99.1 2 ex_224787.htm EXHIBIT 99.1 ex_139495.htm Exhibit 99.1    Net Element Reports Full Year 2020 Financial Results,…
To view the full exhibit click here

About Inc. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

An ad to help with our costs